Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-06-18

Clinical Trial Update: A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ramucirumab (IMC-1121B) in participants with breast cancer has completed and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Breast Cancer, Metastatic Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2014-06-18